Gilead completes Arcellx acquisition

Gilead Sciences has successfully completed its previously announced acquisition of Arcellx, in a deal worth approximately $7.8 billion at the time of closing.

As a result of the completion of the merger, Arcellx has become a wholly owned subsidiary of Gilead. The deal, first revealed in February 2026, gives Gilead full ownership of anito-cel, an investigational BCMA-directed CAR-T cell therapy for multiple myeloma. The therapy has a December 23, 2026 PDUFA date.

Arcellx formed a global strategic collaboration and license agreement to co-develop and co-commercialize anito-cel for patients with relapsed and/or refractory multiple myeloma with Gilead’s Kite in December 2022, expanding it a year later to include the license for Arcellx’s multiple myeloma program and propel treatment of lymphomas.

In clinical studies to date, anito-cel has demonstrated deep and durable responses with a predictable and manageable safety profile, addressing key challenges associated with current CAR T-cell therapies in multiple myeloma. The BLA for anito-cel as a fourth-line treatment for patients with relapsed or refractory multiple myeloma is supported by results from the phase 1 study and the pivotal phase 2 iMMagine1 study.